Belatacept
From Self-sufficiency
| Clinical data | |
|---|---|
| Routes of administration | Intravenous |
| Identifiers | |
| ATC code | none |
Belatacept is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[1] which is a molecule crucial for T-cell costimulation, selectively blocking the process of T-cell activation. It was developed by Bristol-Myers-Squibb. It differs from abatacept (Orencia) by only 2 amino acids.
It is intended to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors.
The FDA is in the process of evaluating a Biologic License Application for Belatacept [2].
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ "Healthvalue.net: CTLA-4 Strategies". Retrieved 2008-10-24.
- ↑ "FDA's Cardiovascular and Renal Drugs Advisory Committee Briefing Document for March 2010 Meeting" (PDF). Retrieved 2010-03-02.
Categories:
- Pages with script errors
- Articles which use infobox templates with no data rows
- Infobox drug articles without a structure image
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Engineered proteins
- Bristol-Myers Squibb
- Pages with broken file links
- Antineoplastic and immunomodulating drug stubs
